Affordable Access

Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses.

Authors
  • Dangaj, Denarda1
  • Scholler, Nathalie
  • 1 Department of Oncology; Ludwig Cancer Research Center; University of Lausanne; Lausanne, Switzerland. , (Switzerland)
Type
Published Article
Journal
Oncoimmunology
Publication Date
Aug 01, 2013
Volume
2
Issue
8
Identifiers
PMID: 24083083
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

B7-H4 inhibits T-cell activation and is widely expressed by solid neoplasms. We have recently demonstrated that the expression of B7-H4 on the surface of malignant cells in vivo is inducible, and that novel anti-B7-H4 recombinant antibodies can reverse the inhibition of tumor-specific T cells. Thus, antibodies targeting the B7-H4 pathways may extend the survival of cancer patients by restoring T cell-mediated antitumor responses.

Report this publication

Statistics

Seen <100 times